Charles Rhyee
Stock Analyst at TD Cowen
(2.17)
# 2,880
Out of 5,149 analysts
75
Total ratings
48%
Success rate
-5.57%
Average return
Main Sectors:
Stocks Rated by Charles Rhyee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TDOC Teladoc Health | Maintains: Hold | $8 → $6 | $5.10 | +17.65% | 7 | Feb 26, 2026 | |
| CRL Charles River Laboratories International | Maintains: Buy | $251 → $235 | $175.69 | +33.76% | 7 | Feb 20, 2026 | |
| TALK Talkspace | Maintains: Buy | $6 → $9 | $4.84 | +85.95% | 3 | Feb 20, 2026 | |
| ICLR ICON Public Limited Company | Upgrades: Buy | $183 → $120 | $108.70 | +10.40% | 7 | Feb 18, 2026 | |
| MEDP Medpace Holdings | Upgrades: Hold | $462 → $419 | $465.38 | -9.97% | 7 | Feb 18, 2026 | |
| CI The Cigna Group | Maintains: Buy | $333 → $338 | $283.93 | +19.04% | 2 | Feb 9, 2026 | |
| MCK McKesson | Maintains: Buy | $1,000 → $1,012 | $995.69 | +1.64% | 5 | Feb 5, 2026 | |
| IQV IQVIA Holdings | Maintains: Hold | $215 → $245 | $173.96 | +40.84% | 3 | Jan 22, 2026 | |
| FTRE Fortrea Holdings | Maintains: Hold | $7 → $15 | $10.48 | +43.13% | 4 | Jan 22, 2026 | |
| MDLN Medline | Initiates: Buy | $46 | $44.39 | +3.63% | 1 | Jan 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $6 | $2.07 | +189.86% | 8 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $350 → $400 | $371.44 | +7.69% | 1 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $99 → $100 | $80.49 | +24.24% | 1 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $183 → $225 | $226.35 | -0.60% | 3 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $30 → $27 | $31.20 | -13.46% | 2 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $297 → $380 | $185.91 | +104.40% | 4 | Oct 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $100 → $50 | $5.15 | +870.87% | 3 | Mar 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $56 | $11.84 | +372.97% | 2 | Oct 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $360 → $280 | $10.30 | +2,618.45% | 3 | Aug 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $50 | $3.51 | +1,324.50% | 2 | Jun 21, 2022 |
Teladoc Health
Feb 26, 2026
Maintains: Hold
Price Target: $8 → $6
Current: $5.10
Upside: +17.65%
Charles River Laboratories International
Feb 20, 2026
Maintains: Buy
Price Target: $251 → $235
Current: $175.69
Upside: +33.76%
Talkspace
Feb 20, 2026
Maintains: Buy
Price Target: $6 → $9
Current: $4.84
Upside: +85.95%
ICON Public Limited Company
Feb 18, 2026
Upgrades: Buy
Price Target: $183 → $120
Current: $108.70
Upside: +10.40%
Medpace Holdings
Feb 18, 2026
Upgrades: Hold
Price Target: $462 → $419
Current: $465.38
Upside: -9.97%
The Cigna Group
Feb 9, 2026
Maintains: Buy
Price Target: $333 → $338
Current: $283.93
Upside: +19.04%
McKesson
Feb 5, 2026
Maintains: Buy
Price Target: $1,000 → $1,012
Current: $995.69
Upside: +1.64%
IQVIA Holdings
Jan 22, 2026
Maintains: Hold
Price Target: $215 → $245
Current: $173.96
Upside: +40.84%
Fortrea Holdings
Jan 22, 2026
Maintains: Hold
Price Target: $7 → $15
Current: $10.48
Upside: +43.13%
Medline
Jan 12, 2026
Initiates: Buy
Price Target: $46
Current: $44.39
Upside: +3.63%
Nov 10, 2025
Maintains: Buy
Price Target: $7 → $6
Current: $2.07
Upside: +189.86%
Nov 10, 2025
Maintains: Buy
Price Target: $350 → $400
Current: $371.44
Upside: +7.69%
Nov 3, 2025
Maintains: Buy
Price Target: $99 → $100
Current: $80.49
Upside: +24.24%
Nov 3, 2025
Maintains: Buy
Price Target: $183 → $225
Current: $226.35
Upside: -0.60%
Nov 3, 2025
Maintains: Hold
Price Target: $30 → $27
Current: $31.20
Upside: -13.46%
Oct 7, 2025
Upgrades: Buy
Price Target: $297 → $380
Current: $185.91
Upside: +104.40%
Mar 23, 2023
Downgrades: Market Perform
Price Target: $100 → $50
Current: $5.15
Upside: +870.87%
Oct 20, 2022
Maintains: Outperform
Price Target: $70 → $56
Current: $11.84
Upside: +372.97%
Aug 16, 2022
Maintains: Outperform
Price Target: $360 → $280
Current: $10.30
Upside: +2,618.45%
Jun 21, 2022
Maintains: Outperform
Price Target: $48 → $50
Current: $3.51
Upside: +1,324.50%